<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=780280282443813&amp;ev=PageView&amp;noscript=1">
search

    Exicure, Inc.

    verified_userVerify Profile
    Companies » Health Care » Pharmaceuticals & Biotechnology » Pharmaceuticals

    About Exicure, Inc.

    Exicure, Inc. is a clinical stage biotechnology company developing a new class of immunomodulatory and gene regulating drugs against validated targets. Exicure's proprietary 3-dimensional, spherical nucleic acid (SNA™) architecture unlocks the potential of therapeutic oligonucleotides in a wide range of cells and tissues. Exicure's lead programs address oncology, inflammatory diseases and genetic disorders. Source

    At A Glance

    • CAPITAL RAISE STATUS
      Not Currently Raising
    • FILING TYPE
      Public
    • PLATFORM TYPE
      NASDAQ
    • RAISED AMOUNT
      $X,XXX,XXX
    • PRE-MONEY EVAULATION
      $X,XXX,XXX
    • SIC CODE
      2834
    • NIN CODE
      ####
    • LEADERSHIP
      David A. Giljohann
    • FOUNDED
      2009
    • EMPLOYEES
      20
    • SECTOR
      Pharmaceuticals & Biotechnology
    • SUBSECTOR
      Pharmaceuticals

    Company Tags

    No articles found.

    Medigus Ltd.

    Medigus Ltd.

    Medigus is a medical device company specializing in developing minimally invasive ...

    Medigus is a medical device company specializin...

    Filing Type:    PU
    Translate Bio, Inc.

    Translate Bio, Inc.

    Translate Bio is a leading mRNA therapeutics company developing a new class of pot...

    Translate Bio is a leading mRNA therapeutics co...

    Filing Type:    PU
    Spok Holdings, Inc.

    Spok Holdings, Inc.

    Spok, Inc., a wholly owned subsidiary of Spok Holdings, Inc. (NASDAQ: SPOK), headq...

    Spok, Inc., a wholly owned subsidiary of Spok H...

    Filing Type:    PU
    uniQure N.V.

    uniQure N.V.

    uniQure is delivering on the promise of gene therapy -- single treatments with pot...

    uniQure is delivering on the promise of gene th...

    Filing Type:    PU
    Cyclacel Pharmaceuticals, Inc.

    Cyclacel Pharmaceuticals, Inc.

    Cyclacel's founding scientist, Professor Sir David Lane, a globally recognized aut...

    Cyclacel's founding scientist, Professor Sir Da...

    Filing Type:    PU
    MEI Pharma, Inc.

    MEI Pharma, Inc.

    MEI Pharma (Nasdaq: MEIP) is a San Diego-based late-stage pharmaceutical company f...

    MEI Pharma (Nasdaq: MEIP) is a San Diego-based ...

    Filing Type:    PU
    Turning Point Therapeutics, Inc.

    Turning Point Therapeutics, Inc.

    Turning Point Therapeutics is a clinical-stage precision oncology company with a p...

    Turning Point Therapeutics is a clinical-stage ...

    Filing Type:    PU
    MacroGenics, Inc.

    MacroGenics, Inc.

    MacroGenics is a clinical-stage biopharmaceutical company focused on discovering a...

    MacroGenics is a clinical-stage biopharmaceutic...

    Filing Type:    PU
    Hutchison China MediTech Limited

    Hutchison China MediTech Limited

    Hutchison China MediTech Limited, known as Chi-Med, is an innovative biopharmaceut...

    Hutchison China MediTech Limited, known as Chi-...

    Filing Type:    PU
    Kiniksa Pharmaceuticals, Ltd.

    Kiniksa Pharmaceuticals, Ltd.

    We are a biopharmaceutical company focused on discovering, acquiring, developing a...

    We are a biopharmaceutical company focused on d...

    Filing Type:    PU
    Provention Bio, Inc.

    Provention Bio, Inc.

    Provention Bio, Inc. is a clinical-stage biopharmaceutical company developing nove...

    Provention Bio, Inc. is a clinical-stage biopha...

    Filing Type:    PU
    Enlivex Therapeutics Ltd.

    Enlivex Therapeutics Ltd.

    Enlivex is a clinical stage immunotherapy company, developing an allogeneic drug p...

    Enlivex is a clinical stage immunotherapy compa...

    Filing Type:    PU
    ©2026 National Investor Network. All Rights Reserved.